Home › Lymphedema › NCT05142800

Screening For BCRL In Targeted Therapy For Breast Cancer

Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer

Who can join

Ages 18 to 80 · Women

Inclusion Criteria:

* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.
* Subjects that will be eligible for the study include:
* Females between 18 and 80 years of age
* With a history of breast cancer
* 4 weeks or more post-surgery
* With or without edema
* Undergoing treatment with targeted therapy for early or metastatic disease.

Exclusion Criteria:

\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).

About the study

This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.

A Perometer and Sozo devise will be used to measure volume changes

What is being tested

• Perometer (device)
• SOZO device (device)

Sponsor: Massachusetts General Hospital · Participants: 261 · Started: Dec 13, 2018

Contact the study team

• Alphonse G. Taghian, MD · Phone: 617-643-1306

Official record on ClinicalTrials.gov — NCT05142800

Locations in the U.S.

Conditions

• Lymphedema
• Edema
• Breast Cancer Lymphedema
• Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.